Arrowhead Research ARWR

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.81 (-4.58%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Arrowhead Research (ARWR)
    Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $16.97

    • Market Cap

      $2.11 Billion

    • Price-Earnings Ratio

      -3.39

    • Total Outstanding Shares

      124.20 Million Shares

    • Total Employees

      525

    • Dividend

      No dividend

    • IPO Date

      January 6, 1997

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      177 e colorado blvd, Pasadena, CA, 91105

    • Homepage

      https://www.arrowheadpharma.com

    Historical Stock Splits

    If you bought 10 shares of ARWR before November 17, 2011, you'd have 1 share today.
    Execution DateSplit Amount
    November 17, 20111-for-10 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-462.85 Million
    Net Cash Flow From Financing Activities, Continuing$870.52 Million
    Exchange Gains/Losses$4.20 Million
    Net Cash Flow From Operating Activities, Continuing$-462.85 Million
    Net Cash Flow From Investing Activities$-420.07 Million
    Net Cash Flow$-8.21 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Operating Expenses$604.63 Million
    Income Tax Expense/Benefit, Deferred$0
    Net Income/Loss Available To Common Stockholders, Basic$-599.49 Million
    Income Tax Expense/Benefit, Current$-2.77 Million
    Revenues$3.55 Million
    Other Operating Expenses$586.04 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-601.72 Million
    Other Comprehensive Income/Loss$7.97 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-601.72 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Current Assets$695.47 Million
    Equity Attributable To Parent$185.44 Million
    Equity Attributable To Noncontrolling Interest$5.62 Million
    Assets$1.14 Billion
    Accounts Payable$11.39 Million
    Fixed Assets$386.03 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ARWR from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.